Fox SH - Search Results

1

Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.

Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Seppi K, et al. Among authors: fox sh. Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Mov Disord. 2019. PMID: 30653247 Free PMC article. Review.

2

5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease.

Fox SH, Brotchie JM. Fox SH, et al. Mov Disord. 2000 Nov;15(6):1064-9. doi: 10.1002/1531-8257(200011)15:6<1064::aid-mds1002>3.0.co;2-c. Mov Disord. 2000. PMID: 11104187

3

Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.

Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J. Fox S, et al. Mov Disord. 2004 May;19(5):554-60. doi: 10.1002/mds.10693. Mov Disord. 2004. PMID: 15133820 Clinical Trial.

4

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Gomez-Ramirez J, Johnston TH, Visanji NP, Fox SH, Brotchie JM. Gomez-Ramirez J, et al. Among authors: fox sh. Mov Disord. 2006 Jun;21(6):839-46. doi: 10.1002/mds.20828. Mov Disord. 2006. PMID: 16532454

5

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.

Fox SH, Lang AE, Brotchie JM. Fox SH, et al. Mov Disord. 2006 Oct;21(10):1578-94. doi: 10.1002/mds.20936. Mov Disord. 2006. PMID: 16874752 Review.

6

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH. Visanji NP, et al. Among authors: fox sh. Mov Disord. 2006 Nov;21(11):1879-91. doi: 10.1002/mds.21073. Mov Disord. 2006. PMID: 16960862

7

Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease.

Thomsen TR, Galpern WR, Asante A, Arenovich T, Fox SH. Thomsen TR, et al. Among authors: fox sh. Mov Disord. 2007 Nov 15;22(15):2268-73. doi: 10.1002/mds.21730. Mov Disord. 2007. PMID: 17876852 Clinical Trial.

8

A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.

Zadikoff C, Fox SH, Tang-Wai DF, Thomsen T, de Bie RM, Wadia P, Miyasaki J, Duff-Canning S, Lang AE, Marras C. Zadikoff C, et al. Among authors: fox sh. Mov Disord. 2008 Jan 30;23(2):297-9. doi: 10.1002/mds.21837. Mov Disord. 2008. PMID: 18044697

9

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH. Visanji NP, et al. Among authors: fox sh. Mov Disord. 2008 Oct 15;23(13):1922-5. doi: 10.1002/mds.22086. Mov Disord. 2008. PMID: 18759357

10

Levodopa-related motor complications--phenomenology.

Fox SH, Lang AE. Fox SH, et al. Mov Disord. 2008;23 Suppl 3:S509-14. doi: 10.1002/mds.22021. Mov Disord. 2008. PMID: 18781677 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

242 results

Search Page

Filters